Format

Send to

Choose Destination
Arthritis Res Ther. 2011 Feb 28;13(1):203. doi: 10.1186/ar3264.

The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.

Author information

1
Department of Internal Medicine, University of Michigan,nn Arbor, MI 48109-5680, USA.

Abstract

Patients with systemic lupus erythematosus have up to a 50-fold increased risk of developing atherosclerotic cardiovascular disease. Recent advances in the etiology of vascular damage in this disease stress the interplay of lupus-specific inflammatory factors with traditional cardiac risk factors, leading to increased endothelial damage. This review analyzes the putative role that immune dysregulation and lupus-specific factors may play in the pathogenesis of premature vascular damage in this disease. The potential role of various cytokines, in particular type I interferons, in the development of accelerated atherosclerosis is examined. Potential therapeutic targets are discussed.

PMID:
21371346
PMCID:
PMC3157642
DOI:
10.1186/ar3264
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center